Clinical Adoption SCINTIX biology-guided radiotherapy is FDA-cleared and delivers real-time, tumor-responsive treatment for lung and bone cancers. This creates an opportunity to pitch to oncology programs focused on precision radiotherapy, patient throughput, and improved treatment outcomes.

Theranostic Partners Strategic licensing and collaboration with 3B Pharmaceuticals to develop targeted radiopharmaceuticals guiding SCINTIX expands potential indications. Target biopharma, imaging centers, and cancer centers for bundled theranostic offerings and joint development.

Growth Readiness Recent funding and executive leadership changes signal capacity for broader deployment and scaled service. Use this to engage procurement with a solid ROI case, total cost of ownership, and multi-site deployment proposals.

Competitive Edge Biology-guided radiotherapy differentiates RefleXion from traditional radiotherapy vendors and can appeal to centers evaluating alternatives. Position as a modern, precision-focused platform with potential for expanded patient access.

IT Interoperability HIPAA compliance and cloud-enabled tools (Azure, Tableau) indicate readiness to integrate with hospital IT and data analytics. Propose EHR/EMR integration, secure data workflows, and real-time outcome dashboards.